Related Experiment Video
Updated: Aug 9, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic
Calum J Redpath1, Andrew C Rankin, Kathleen A Kane
1Division of Cardiovascular and Medical Sciences, University of Glasgow, UK.
Insights
Endothelin-1 (ET-1) counteracts isoproterenol's pro-arrhythmic effects in human atrial cells by reducing action potential duration and L-type calcium current. This suggests ET-1 may offer an anti-arrhythmic benefit in patients with atrial fibrillation and heart failure.
Area of Science:
- Cardiovascular Electrophysiology
- Pharmacology
- Cellular Biology
Background:
- Elevated Endothelin-1 (ET-1) levels are observed in patients with atrial fibrillation (AF) and heart failure.
- The electrophysiological effects of ET-1 in human atria, particularly concerning AF mechanisms, require further investigation.
Purpose of the Study:
- To investigate the effects of ET-1 on human atrial cellular electrophysiology.
- To determine ET-1's influence on action potential characteristics and L-type Ca(2+) current (I(CaL)) in the context of AF.
Main Methods:
- Whole-cell patch clamp technique was used to record action potential characteristics and I(CaL) in isolated human atrial myocytes from patients in sinus rhythm.
- Cells were treated with isoproterenol (ISO) and/or ET-1 to assess their electrophysiological responses.
Main Results:
- Isoproterenol (ISO) prolonged action potential duration (APD(50)) and induced arrhythmic depolarizations, while increasing peak I(CaL).
- ET-1 (10 nM) reversed ISO-induced APD(50) prolongation and abolished arrhythmic depolarizations.
- ET-1 significantly inhibited ISO-stimulated I(CaL) by approximately 98% without affecting basal I(CaL) or effective refractory period (ERP).
Conclusions:
- ET-1 exhibits significant anti-adrenergic effects on human atrial electrophysiology, specifically on action potential plateau and I(CaL).
- These anti-arrhythmic properties of ET-1, independent of beta-blocker treatment, may confer a protective influence against AF in patients with heart failure.
Abstract:
Endothelin-1 (ET-1) is elevated in patients with atrial fibrillation (AF) and heart failure. We investigated effects of ET-1 on human atrial cellular electrophysiological measurements expected to influence the genesis and maintenance of AF. Action potential characteristics and L-type Ca(2+) current (I(CaL)) were recorded by whole cell patch clamp, in atrial isolated myocytes obtained from patients in sinus rhythm. Isoproterenol (ISO) at 0.05 muM prolonged the action potential duration at 50% repolarisation (APD(50): 54 +/- 10 vs. 28 +/- 5 ms; P < 0.05, N = 15 cells, 10 patients), but neither late repolarisation nor cellular effective refractory period (ERP) were affected. ET-1 (10 nM) reversed the effect of ISO on APD(50), and had no basal effect (in the absence of ISO) on repolarisation or ERP. During repetitive stimulation, ISO (0.05 microM) produced arrhythmic depolarisations (P < 0.05). Each was abolished by ET-1 at 10 nM (P < 0.05). ISO (0.05 microM) increased peak I(CaL) from -5.5 +/- 0.4 to -14.6 +/- 0.9 pA/pF (P < 0.05; N = 79 cells, 34 patients). ET-1 (10 nM) reversed this effect by 98 +/- 10% (P < 0.05), with no effect on basal I(CaL). Chronic treatment of patients with a beta-blocker did not significantly alter basal APD(50) or I(CaL), the increase in APD(50) or I(CaL) by 0.05 microM ISO, nor the subsequent reversal of this effect on APD(50) by 10 nM ET-1. The marked anti-adrenergic effects of ET-1 on human atrial cellular action potential plateau, arrhythmic depolarisations and I(CaL), without affecting ERP and independently of beta-blocker treatment, may be expected to contribute a potentially anti-arrhythmic influence in the atria of patients with AF and heart failure.
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
